A Randomized Phase II Study of Anti-CSF-1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple Negative Breast Cancer.

Kuemmel, Sherko; Campone, Mario; Loirat, Delphine; López López, Rafael; Beck, J; De Laurentiis, Michelino; Im, Seock-Ah; Kim, Sung-Bae; Kwong, Ava; Steger, Guenther; Zamora Adelantado, Esther; Duhoux, Francois; Greil, Richard; Kuter, Irene; Lu, Yen-Shen; Tibau, Ariadna; Özgüroğlu, MUSTAFA; Scholz, Christian; Singer, Christian; Vega, Estela; Wimberger, Pauline; Zamagni, Claudio; Couillebault, Xuan-Mai; Fan, Liqiong; Guerreiro, Nelson; Mataraza, Jennifer; Sand-Dejmek, Janna; Chan, Arlene

doi:10.1158/1078-0432.ccr-20-3955

A Randomized Phase II Study of Anti-CSF-1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple Negative Breast Cancer.

Kuemmel S., Campone M., Loirat D., López López R., Beck J. T., De Laurentiis M., ...Daha Fazla

Clinical cancer research : an official journal of the American Association for Cancer Research, cilt.28, ss.106-115, 2022 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 28
Basım Tarihi: 2022
Doi Numarası: 10.1158/1078-0432.ccr-20-3955
Dergi Adı: Clinical cancer research : an official journal of the American Association for Cancer Research
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, BIOSIS, Biotechnology Research Abstracts, EMBASE, Gender Studies Database, MEDLINE
Sayfa Sayıları: ss.106-115
İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Purpose: This phase II study determined the efficacy of lacnotuzumab added to gemcitabine plus carboplatin (gem-carbo) in patients with advanced triple-negative breast cancer (TNBC).